Abstract
Pharmacists are using a variety of techniques to ensure that pharmaceuticals produced by recombinant technology improve patient outcomes without blowing pharmacy budgets. Recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were the focus of several presentations at the 28th Midyear Clinical Meeting of the American Society of Hospital Pharmacists, held in Atlanta, Georgia last December. Key areas in which pharmacists participate in optimising the use of these drugs include exploiting synergistic effects of treatment, determining treatment guidelines and minimising inappropriate use of these high-price agents.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
